Approximately 66 percent of the top 50 pharma are engaged in or are planning to adopt an Electronic Informed Consent Form (e-ICF) or e-Consent initiative in the near future with most of the top 10 pharma already having an e-Consent strategy in place. In 3 years from now, e-Consent is expected to be used in more than 75 percent of clinical trials, with 94-96 percent of patients already preferring e-Consent. The flexible device approach is predicted to have the highest rate of adoption of 65 percent in 3-5 years, followed by a 60 percent adoption rate of mutual recognition training. ..
The report provides a comprehensive analysis of the e-Consent market, the factors affecting the market, and methods to improve e-Consent adoption by Pharma. The report examines current and future trends in the e-Consent market, along with a SWOT analysis. The report identifies the industry best practices and benchmarks on service offerings, with relevant case studies. Opportunities for different stakeholders are evaluated in the report, and the regulatory landscape in the U.S. and EU applicable to e-Consent are discussed. The report also includes a detailed supplier analysis with supplier landscape and relevant selection criteria and analysis of major collaborations by suppliers.
Beroe gathers intelligence through primary sources that include industry experts, researchers, and consultants, as well as current suppliers, producers and distributors. Secondary sources can include business journals, newsletters, magazines, market research data, company sources, and industry associations. Following data collation, analysis, and strategic review, the Final Research Report is published on Beroe LiVE.
Category Intelligence on e-Consent covers the following
Although historically there has been challenges in adopting to e-Consent platform, currently there is shift in the industry. Most of the top 10 Pharma have incorporated in almost 60 percent of their trials. Buyers who were adopting at a rate of 10-11 percent last year are turning to a higher percent of adoption, close to 21-23 percent now.
Suppliers are collaborating with technology providers and amongst themselves to promote site and patient acceptance to e-Consent. Existing and new suppliers are broadening their scope of their service to align themselves to the industry shift and demand.
Complimentary 12-month access to Beroe LiVE
COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)